praziquantel has been researched along with Pregnancy in 65 studies
azinox: Russian drug
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mass drug administration (MDA) of praziquantel is one of the main control measures against human schistosomiasis." | 9.41 | A cluster randomized controlled trial for assessing POC-CCA test based praziquantel treatment for schistosomiasis control in pregnant women and their young children: study protocol of the freeBILy clinical trial in Madagascar. ( Adegnika, AA; Andrianarivelo, MR; Corstjens, PLAM; Dechenaud, M; Fusco, D; Hoekstra, PT; Jaeger, A; Klein, P; Kreidenweiss, A; Lorenz, E; May, J; Puradiredja, DI; Rakotoarivelo, RA; Rakotozandrindrainy, N; Rakotozandrindrainy, R; Rasamoelina, T; Schwarz, NG; Sicuri, E; Stahlberg, K; van Dam, GJ, 2021) |
| " Praziquantel (PZQ) treatment for Schistosoma japonicum infection in pregnant women has been demonstrated to be safe and effective." | 9.41 | Effect of maternal praziquantel treatment for Schistosoma japonicum infection on the offspring susceptibility and immunologic response to infection at age six, a cohort study. ( Acosta, LP; Baltazar, P; Barry, CV; Colt, S; Friedman, JF; Jarilla, B; Jiz, MA; Kurtis, JD; Olveda, RM; Tallo, V; Wu, HW, 2021) |
| "com/ISRCTN32849447/elliott), offspring of women treated with praziquantel or placebo during pregnancy were examined for S." | 9.17 | Effect of maternal Schistosoma mansoni infection and praziquantel treatment during pregnancy on Schistosoma mansoni infection and immune responsiveness among offspring at age five years. ( Cose, S; Dunne, DW; Elliott, AM; Jones, FM; Mawa, PA; Naniima, P; Tweyongyere, R; Webb, EL, 2013) |
| "Despite strong effects on maternal infection intensity and maternal immune responses, praziquantel treatment of infected women during pregnancy had no effect on anti-schistosome immune responses among offspring by age one year." | 9.15 | Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on immune responses to schistosome antigens among the offspring: results of a randomised, placebo-controlled trial. ( Cose, S; Dunne, DW; Elliott, AM; Jones, FM; Kihembo, M; Mawa, PA; Tweyongyere, R; Vennervald, BJ; Webb, EL, 2011) |
| " At six weeks after praziquantel treatment during pregnancy S." | 9.14 | Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo-controlled trial. ( Dunne, DW; Duong, T; Elliott, AM; Emojong, NO; Jones, FM; Katunguka-Rwakishaya, E; Mawa, PA; Mpairwe, H; Tweyongyere, R; Vennervald, BJ, 2009) |
| "Pregnancy suppresses a potentially beneficial boost in cytokine responses associated with praziquantel treatment." | 9.13 | Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo-controlled trial. ( Dunne, DW; Duong, T; Elliott, AM; Katunguka-Rwakishaya, E; Mawa, PA; Ndibazza, J; Ngom-Wegi, S; Tweyongyere, R; Vennervald, BJ, 2008) |
| " Additional investigations of the proportion of newborns with FGR should obtain more certainty about the effect of praziquantel and schistosomiasis on fetal growth." | 8.31 | Investigation on birth weight outcomes in schistosomiasis and praziquantel research: a correspondence. ( Davi, SD; Holtfreter, MC; Mischlinger, J; Schleenvoigt, BT, 2023) |
| "In a prospective study carried out in New Halfa Teaching Hospital, in eastern Sudan, between June 2001 and April 2003, 25 pregnant Sudanese women with schistosomiasis mansoni were each treated with a single oral dose of praziquantel (PZQ), at 40 mg/kg." | 7.73 | Praziquantel for the treatment of schistosomiasis mansoni during pregnancy. ( Adam, I; Elwasila, E; Homeida, M, 2005) |
| "Schistosomiasis control programmes are generally based on mass distribution of praziquantel (PZQ)." | 7.72 | Is praziquantel therapy safe during pregnancy? ( Adam, I; Elwasila, el T; Homeida, M, 2004) |
| "Treatment with praziquantel did not have a significant effect on birthweight (2·85 kg in both groups, β=-0·002 [95% CI -0·088 to 0·083]; p=0·962)." | 6.82 | Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial. ( Acosta, LP; Ayaso, EB; Baltazar, PI; Estanislao, GG; Friedman, JF; Ida, A; Kurtis, JD; Lesiguez, JL; McDonald, EA; Monterde, DB; Olveda, RM; Tallo, V; Watson, N; Wu, HW, 2016) |
| "Mass drug administration (MDA) of praziquantel is one of the main control measures against human schistosomiasis." | 5.41 | A cluster randomized controlled trial for assessing POC-CCA test based praziquantel treatment for schistosomiasis control in pregnant women and their young children: study protocol of the freeBILy clinical trial in Madagascar. ( Adegnika, AA; Andrianarivelo, MR; Corstjens, PLAM; Dechenaud, M; Fusco, D; Hoekstra, PT; Jaeger, A; Klein, P; Kreidenweiss, A; Lorenz, E; May, J; Puradiredja, DI; Rakotoarivelo, RA; Rakotozandrindrainy, N; Rakotozandrindrainy, R; Rasamoelina, T; Schwarz, NG; Sicuri, E; Stahlberg, K; van Dam, GJ, 2021) |
| " Praziquantel (PZQ) treatment for Schistosoma japonicum infection in pregnant women has been demonstrated to be safe and effective." | 5.41 | Effect of maternal praziquantel treatment for Schistosoma japonicum infection on the offspring susceptibility and immunologic response to infection at age six, a cohort study. ( Acosta, LP; Baltazar, P; Barry, CV; Colt, S; Friedman, JF; Jarilla, B; Jiz, MA; Kurtis, JD; Olveda, RM; Tallo, V; Wu, HW, 2021) |
| "Samples from a study designed to examine Praziquantel treatment during pregnancy were used (n = 359)." | 5.30 | Maternal anemia type during pregnancy is associated with anemia risk among offspring during infancy. ( Abioye, AI; Acosta, LP; Amoylen, AJ; Baltazar, PI; Bennett, B; Friedman, JF; Kurtis, JD; McDonald, EA; Olveda, RM; Park, S; Pond-Tor, S; Ripp, K; Sagliba, MJ; Tallo, V; Wu, HW, 2019) |
| " During pregnancy, women were randomized, simultaneously, to albendazole vs placebo and to praziquantel vs placebo." | 5.24 | Effects of treating helminths during pregnancy and early childhood on risk of allergy-related outcomes: Follow-up of a randomized controlled trial. ( Akello, F; Akurut, H; Elliott, AM; Kabagenyi, J; Kizza, M; Lule, SA; Mpairwe, H; Muhangi, L; Muwanga, M; Namara, B; Nash, S; Nkurunungi, G; Tumusiime, J; Webb, EL, 2017) |
| "com/ISRCTN32849447/elliott), offspring of women treated with praziquantel or placebo during pregnancy were examined for S." | 5.17 | Effect of maternal Schistosoma mansoni infection and praziquantel treatment during pregnancy on Schistosoma mansoni infection and immune responsiveness among offspring at age five years. ( Cose, S; Dunne, DW; Elliott, AM; Jones, FM; Mawa, PA; Naniima, P; Tweyongyere, R; Webb, EL, 2013) |
| "To investigate the effect of helminth infections and their treatment during pregnancy on HIV load, we conducted a 2 × 2 factorial randomized controlled trial of albendazole versus placebo and praziquantel versus placebo in pregnant women in Entebbe, Uganda." | 5.16 | The effect of anthelmintic treatment during pregnancy on HIV plasma viral load: results from a randomized, double-blind, placebo-controlled trial in Uganda. ( Elliott, AM; Kaleebu, P; Kizito, D; Kyosiimire-Lugemwa, J; Lule, S; Muhangi, L; Muwanga, M; Nkurunziza, P; Webb, EL, 2012) |
| "Despite strong effects on maternal infection intensity and maternal immune responses, praziquantel treatment of infected women during pregnancy had no effect on anti-schistosome immune responses among offspring by age one year." | 5.15 | Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on immune responses to schistosome antigens among the offspring: results of a randomised, placebo-controlled trial. ( Cose, S; Dunne, DW; Elliott, AM; Jones, FM; Kihembo, M; Mawa, PA; Tweyongyere, R; Vennervald, BJ; Webb, EL, 2011) |
| "A randomised, double-blind, placebo-controlled trial on treatment in pregnancy with albendazole versus placebo and praziquantel versus placebo was conducted in Uganda, with a 2 × 2 factorial design; 2507 women were enrolled; infants' allergy events were recorded prospectively." | 5.15 | Anthelminthic treatment during pregnancy is associated with increased risk of infantile eczema: randomised-controlled trial results. ( Akishule, D; Dunne, DW; Elliott, AM; Fitzsimmons, C; Jones, FM; Mpairwe, H; Muhangi, L; Muwanga, M; Nampijja, M; Ndibazza, J; Ngom-wegi, S; Rodrigues, LC; Tumusime, J; Webb, EL, 2011) |
| " At six weeks after praziquantel treatment during pregnancy S." | 5.14 | Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo-controlled trial. ( Dunne, DW; Duong, T; Elliott, AM; Emojong, NO; Jones, FM; Katunguka-Rwakishaya, E; Mawa, PA; Mpairwe, H; Tweyongyere, R; Vennervald, BJ, 2009) |
| "Pregnancy suppresses a potentially beneficial boost in cytokine responses associated with praziquantel treatment." | 5.13 | Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo-controlled trial. ( Dunne, DW; Duong, T; Elliott, AM; Katunguka-Rwakishaya, E; Mawa, PA; Ndibazza, J; Ngom-Wegi, S; Tweyongyere, R; Vennervald, BJ, 2008) |
| "The commitment to eliminate schistosomiasis as a public health problem has mobilized the expansion of praziquantel treatment to meet the London Declaration targets." | 4.98 | Acting beyond 2020: better characterization of praziquantel and promising antischistosomal leads. ( Keiser, J; Panic, G, 2018) |
| "An action plan for paediatric schistosomiasis and female genital schistosomiasis (FGS) is needed with expanded access to praziquantel (PZQ) treatment required." | 4.95 | Paediatric and maternal schistosomiasis: shifting the paradigms. ( Bustinduy, AL; Friedman, JF; Stothard, JR, 2017) |
| "Praziquantel (PZQ) is the safest of all anti-helminthics and now forms the backbone for all national control programs against schistosomiasis (Med." | 4.82 | Administration of praziquantel to pregnant and lactating women. ( Olds, GR, 2003) |
| " Additional investigations of the proportion of newborns with FGR should obtain more certainty about the effect of praziquantel and schistosomiasis on fetal growth." | 4.31 | Investigation on birth weight outcomes in schistosomiasis and praziquantel research: a correspondence. ( Davi, SD; Holtfreter, MC; Mischlinger, J; Schleenvoigt, BT, 2023) |
| "In a prospective study carried out in New Halfa Teaching Hospital, in eastern Sudan, between June 2001 and April 2003, 25 pregnant Sudanese women with schistosomiasis mansoni were each treated with a single oral dose of praziquantel (PZQ), at 40 mg/kg." | 3.73 | Praziquantel for the treatment of schistosomiasis mansoni during pregnancy. ( Adam, I; Elwasila, E; Homeida, M, 2005) |
| "Schistosomiasis control programmes are generally based on mass distribution of praziquantel (PZQ)." | 3.72 | Is praziquantel therapy safe during pregnancy? ( Adam, I; Elwasila, el T; Homeida, M, 2004) |
| "Praziquantel treatment did not significantly alter the trajectory of the concentration of any of the cytokines examined." | 2.90 | Maternal, placental and cord blood cytokines and the risk of adverse birth outcomes among pregnant women infected with Schistosoma japonicum in the Philippines. ( Abioye, AI; Acosta, LP; Baltazar, P; Ernerudh, J; Friedman, JF; Joshi, A; Kurtis, JD; McDonald, EA; Olveda, RM; Park, S; Pond-Tor, S; Sharma, S; Tallo, V; Wu, H, 2019) |
| "Treatment with praziquantel did not have a significant effect on birthweight (2·85 kg in both groups, β=-0·002 [95% CI -0·088 to 0·083]; p=0·962)." | 2.82 | Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial. ( Acosta, LP; Ayaso, EB; Baltazar, PI; Estanislao, GG; Friedman, JF; Ida, A; Kurtis, JD; Lesiguez, JL; McDonald, EA; Monterde, DB; Olveda, RM; Tallo, V; Watson, N; Wu, HW, 2016) |
| "Deworming during pregnancy has therefore been strongly advocated, but its benefits have not been rigorously evaluated." | 2.75 | Effects of deworming during pregnancy on maternal and perinatal outcomes in Entebbe, Uganda: a randomized controlled trial. ( Akishule, D; Ameke, C; Duong, T; Elliott, AM; Kiggundu, M; Kizindo, R; Kleinschmidt, I; Muhangi, L; Muwanga, M; Ndibazza, J; Oweka, J, 2010) |
| " Neither adverse effects on mares nor abortions occurred." | 2.71 | Evaluation of the safety of ivermectin-praziquantel administered orally to pregnant mares. ( Alves-Branco, F; Mercier, P; Sapper, Mde F; White, CR, 2003) |
| "Praziquantel is a synthetic drug with a remarkable activity against parasites, particularly treamatodes and cestodes." | 2.40 | Genotoxic activity of praziquantel. ( Montero, R; Ostrosky, P, 1997) |
| "Schistosoma intercalatum bilharziasis continues to raise numerous questions regarding pathogenicity and gravity." | 2.40 | [Schistosoma intercalatum bilharziasis: clinical and epidemiological considerations]. ( De Muynck, A; Jusot, JF; Simarro, PP, 1997) |
| "Schistosomiasis is a neglected tropical disease (NTD) that is endemic in Uganda, despite several interventions to eliminate it." | 1.91 | Gendered lives, gendered Vulnerabilities: An intersectional gender analysis of exposure to and treatment of schistosomiasis in Pakwach district, Uganda. ( Morgan, R; Nakiranda, S; Opio, CK; Otmani Del Barrio, M; Ssali, SN, 2023) |
| "Praziquantel was safe and effective." | 1.43 | A case report of Schistosoma haematobium infection in a pregnant migrant raises concerns about lack of screening policies. ( Focà, A; Giancotti, A; Liberto, MC; Loria, MT; Matera, G; Mazzitelli, M; Peronace, C; Settembre, P; Strazzulla, A; Torti, C; Visconti, F; Votino, C; Zullo, F, 2016) |
| " The results of this study indicate that 50 mg/kg oral praziquantel is required for efficacious dosing and that this dose rate is safe in llamas and thus is recommended for the treatment of camelids naturally infected with D." | 1.39 | Efficacy and safety of oral praziquantel against Dicrocoelium dendriticum in llamas. ( Dadak, AM; Franz, S; Joachim, A; Wieser, C, 2013) |
| "Schistosomal tubal obstructions are the cause of ectopic pregnancies and infertility not to be forgotten in endemic areas." | 1.32 | [Extra uterine pregnancy associated with a tubal schistosomiasis due to Schistosoma haematobium. A case report from Niger]. ( Almoustapha, T; Garba, A; Garba, M; Nouhou, H, 2004) |
| "Schistosomiasis is endemic in many parts of the tropics and subtropics with an estimated 200 million people, at least, infected worldwide." | 1.31 | Localized papular cutaneous schistosomiasis: two cases in travellers. ( Leman, JA; Small, G; Tidman, MJ; Wilks, D, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (7.69) | 18.7374 |
| 1990's | 9 (13.85) | 18.2507 |
| 2000's | 17 (26.15) | 29.6817 |
| 2010's | 23 (35.38) | 24.3611 |
| 2020's | 11 (16.92) | 2.80 |
| Authors | Studies |
|---|---|
| Fusco, D | 1 |
| Rakotozandrindrainy, R | 3 |
| Rakotoarivelo, RA | 3 |
| Andrianarivelo, MR | 2 |
| Rakotozandrindrainy, N | 1 |
| Rasamoelina, T | 2 |
| Puradiredja, DI | 1 |
| Klein, P | 1 |
| Stahlberg, K | 1 |
| Dechenaud, M | 1 |
| Lorenz, E | 1 |
| Jaeger, A | 1 |
| Kreidenweiss, A | 3 |
| Hoekstra, PT | 3 |
| Adegnika, AA | 3 |
| Sicuri, E | 3 |
| Corstjens, PLAM | 3 |
| van Dam, GJ | 3 |
| May, J | 1 |
| Schwarz, NG | 3 |
| Mielke, N | 1 |
| Johnson, S | 1 |
| Bahl, A | 1 |
| Fadladdin, YAJ | 1 |
| Xue, M | 1 |
| Zhang, X | 1 |
| Chen, J | 1 |
| Liu, F | 1 |
| Xu, J | 1 |
| Xie, J | 1 |
| Yang, Y | 1 |
| Yu, W | 1 |
| Qiu, H | 1 |
| Xue, J | 1 |
| Jiang, J | 1 |
| Liu, Y | 2 |
| Shallom, SJ | 1 |
| Zelazny, AM | 1 |
| Giri, AR | 1 |
| Kaur, N | 1 |
| Yarrarapu, SNS | 1 |
| Rottman Pietrzak, KA | 1 |
| Santos, C | 1 |
| Lowman, PE | 1 |
| Niaz, S | 1 |
| Franco, PM | 1 |
| Sanghavi, DK | 1 |
| Zhu, D | 1 |
| Liang, R | 1 |
| Li, Z | 2 |
| Cheng, L | 1 |
| Ren, J | 1 |
| Guo, Y | 1 |
| Wang, M | 1 |
| Chai, H | 1 |
| Niu, Q | 1 |
| Yang, S | 1 |
| Bai, J | 1 |
| Yu, H | 1 |
| Zhang, H | 1 |
| Qin, X | 1 |
| Sahrakorpi, N | 1 |
| Engberg, E | 1 |
| Stach-Lempinen, B | 1 |
| Tammelin, TH | 1 |
| Kulmala, J | 1 |
| Roine, RP | 1 |
| Koivusalo, SB | 1 |
| Cheng, W | 1 |
| Pang, H | 1 |
| Campen, MJ | 1 |
| Zhang, J | 2 |
| Li, Y | 1 |
| Gao, J | 1 |
| Ren, D | 1 |
| Ji, X | 1 |
| Rothman, N | 1 |
| Lan, Q | 1 |
| Zheng, Y | 1 |
| Leng, S | 1 |
| Hu, Z | 1 |
| Tang, J | 1 |
| Dong, Q | 1 |
| Song, N | 1 |
| Qin, N | 1 |
| Chen, C | 1 |
| Sun, X | 1 |
| Easton, J | 1 |
| Mulder, H | 1 |
| Plyler, E | 1 |
| Neale, G | 1 |
| Walker, E | 1 |
| Li, Q | 1 |
| Ma, X | 1 |
| Chen, X | 1 |
| Huang, IC | 1 |
| Yasui, Y | 1 |
| Ness, KK | 1 |
| Hudson, MM | 1 |
| Robison, LL | 1 |
| Wang, Z | 1 |
| Subota, A | 1 |
| Spotswood, N | 1 |
| Roach, M | 1 |
| Goodarzi, Z | 1 |
| Holroyd-Leduc, J | 1 |
| Park, EA | 1 |
| Graves, SA | 1 |
| Menda, Y | 1 |
| Lacorcia, M | 1 |
| Kugyelka, R | 1 |
| Spechtenhauser, L | 1 |
| Prodjinotho, UF | 1 |
| Hamway, Y | 1 |
| Spangenberg, T | 1 |
| da Costa, CP | 1 |
| Cunningham, FG | 1 |
| Twickler, DM | 1 |
| Holtfreter, MC | 1 |
| Mischlinger, J | 1 |
| Davi, SD | 1 |
| Schleenvoigt, BT | 1 |
| Ssali, SN | 1 |
| Morgan, R | 1 |
| Nakiranda, S | 1 |
| Opio, CK | 1 |
| Otmani Del Barrio, M | 1 |
| Bustinduy, AL | 2 |
| Kolamunnage-Dona, R | 1 |
| Mirochnick, MH | 1 |
| Capparelli, EV | 1 |
| Tallo, V | 5 |
| Acosta, LP | 5 |
| Olveda, RM | 5 |
| Friedman, JF | 7 |
| Hope, WW | 1 |
| Honkpehedji, YJ | 1 |
| Dejon-Agobe, JC | 1 |
| Zinsou, JF | 1 |
| Mba, RB | 1 |
| Gerstenberg, J | 1 |
| Tielemans, E | 1 |
| Erasmus, H | 1 |
| Momberg, M | 1 |
| Pfefferkorn, A | 1 |
| Targa, N | 1 |
| Chilakapati, J | 1 |
| Gupta, A | 1 |
| Colt, S | 1 |
| Jarilla, B | 1 |
| Baltazar, P | 2 |
| Wu, HW | 3 |
| Barry, CV | 1 |
| Kurtis, JD | 5 |
| Jiz, MA | 1 |
| Namara, B | 1 |
| Nash, S | 2 |
| Lule, SA | 2 |
| Akurut, H | 2 |
| Mpairwe, H | 5 |
| Akello, F | 1 |
| Tumusiime, J | 1 |
| Kizza, M | 3 |
| Kabagenyi, J | 1 |
| Nkurunungi, G | 1 |
| Muhangi, L | 7 |
| Webb, EL | 7 |
| Muwanga, M | 7 |
| Elliott, AM | 13 |
| Stothard, JR | 1 |
| Camprubí, D | 1 |
| Requena-Méndez, A | 1 |
| Rodríguez, N | 1 |
| Valls, ME | 1 |
| García-Herrera, A | 1 |
| Estrach, T | 1 |
| Fustà, X | 1 |
| García-Bernalt Diego, J | 1 |
| Fernández-Soto, P | 1 |
| Muñoz, J | 1 |
| Panic, G | 1 |
| Keiser, J | 1 |
| Abioye, AI | 2 |
| McDonald, EA | 3 |
| Park, S | 2 |
| Ripp, K | 1 |
| Bennett, B | 1 |
| Pond-Tor, S | 2 |
| Sagliba, MJ | 1 |
| Amoylen, AJ | 1 |
| Baltazar, PI | 2 |
| Joshi, A | 1 |
| Wu, H | 1 |
| Sharma, S | 1 |
| Ernerudh, J | 1 |
| Dadak, AM | 1 |
| Wieser, C | 1 |
| Joachim, A | 1 |
| Franz, S | 1 |
| Benti, H | 1 |
| Tweyongyere, R | 6 |
| Naniima, P | 1 |
| Mawa, PA | 5 |
| Jones, FM | 4 |
| Cose, S | 2 |
| Dunne, DW | 5 |
| Aminu, MB | 1 |
| Abdullahi, K | 1 |
| Dattijo, LM | 1 |
| Böhm, C | 1 |
| Petry, G | 1 |
| Schaper, R | 2 |
| Wolken, S | 2 |
| Strube, C | 1 |
| Luty, AJ | 1 |
| Lesiguez, JL | 1 |
| Estanislao, GG | 1 |
| Ayaso, EB | 1 |
| Monterde, DB | 1 |
| Ida, A | 1 |
| Watson, N | 1 |
| Qian, C | 1 |
| Gong, F | 1 |
| Mazzitelli, M | 1 |
| Matera, G | 1 |
| Votino, C | 1 |
| Visconti, F | 1 |
| Strazzulla, A | 1 |
| Loria, MT | 1 |
| Peronace, C | 1 |
| Settembre, P | 1 |
| Giancotti, A | 1 |
| Liberto, MC | 1 |
| Focà, A | 1 |
| Zullo, F | 1 |
| Torti, C | 1 |
| Mentzer, AJ | 1 |
| Kizito, D | 4 |
| Smits, G | 1 |
| van der Klis, FR | 1 |
| Ngom-Wegi, S | 2 |
| Ndibazza, J | 6 |
| Duong, T | 3 |
| Vennervald, BJ | 3 |
| Katunguka-Rwakishaya, E | 2 |
| Emojong, NO | 1 |
| Mencke, N | 1 |
| Kraemer, F | 1 |
| Schnieder, T | 1 |
| Akishule, D | 2 |
| Kiggundu, M | 1 |
| Ameke, C | 2 |
| Oweka, J | 1 |
| Kizindo, R | 2 |
| Kleinschmidt, I | 1 |
| Smith, JL | 1 |
| Brooker, S | 1 |
| Namatovu, A | 1 |
| Kyosiimire-Lugemwa, J | 2 |
| Nanteza, B | 1 |
| Nampijja, M | 3 |
| Woodburn, PW | 1 |
| Akello, M | 1 |
| Lyadda, N | 1 |
| Bukusuba, J | 1 |
| Kihembo, M | 2 |
| Nabulime, J | 1 |
| Namujju, PB | 2 |
| Whitworth, JA | 2 |
| Tumusime, J | 1 |
| Fitzsimmons, C | 1 |
| Rodrigues, LC | 1 |
| Mawa, P | 1 |
| Nkurunziza, P | 1 |
| Lule, S | 1 |
| Kaleebu, P | 1 |
| Olds, GR | 2 |
| Hoffmann, H | 1 |
| Bauerfeind, I | 1 |
| Mercier, P | 1 |
| Alves-Branco, F | 1 |
| Sapper, Mde F | 1 |
| White, CR | 1 |
| Chitsulo, L | 1 |
| Loverde, P | 1 |
| Engels, D | 1 |
| Garba, M | 1 |
| Almoustapha, T | 1 |
| Garba, A | 1 |
| Nouhou, H | 1 |
| Johansen, MV | 1 |
| Ornbjerg, N | 1 |
| Adam, I | 2 |
| Elwasila, el T | 1 |
| Homeida, M | 2 |
| Elwasila, E | 1 |
| Quigley, MA | 1 |
| Morison, L | 1 |
| Kabatereine, N | 1 |
| Mital, P | 1 |
| Kanzaria, HK | 1 |
| Murugesh, M | 1 |
| Veerendra, S | 1 |
| Madhu, S | 1 |
| Kude, S | 1 |
| Amrapurkar, AD | 1 |
| Rathi, UU | 1 |
| Rathi, PM | 1 |
| Pistone, T | 1 |
| Ezzedine, K | 1 |
| Accoceberry, I | 1 |
| Receveur, MC | 1 |
| Juguet, F | 1 |
| Malvy, D | 1 |
| Frohberg, H | 1 |
| Ni, YC | 2 |
| Shao, BR | 1 |
| Zhan, CQ | 1 |
| Xu, YQ | 1 |
| Ha, SH | 1 |
| Jiao, PY | 1 |
| Krolikowski, A | 1 |
| Janowski, K | 1 |
| Larsen, JV | 1 |
| Wirth, HP | 1 |
| Casanova, C | 1 |
| Meyenberger, C | 1 |
| Hammer, B | 1 |
| Ammann, R | 1 |
| Blum, HE | 1 |
| Michel-Harder, C | 1 |
| Gubler, C | 1 |
| Paparone, PW | 1 |
| Menghetti, RA | 1 |
| Montero, R | 1 |
| Ostrosky, P | 1 |
| Jusot, JF | 1 |
| Simarro, PP | 1 |
| De Muynck, A | 1 |
| Viggers, KL | 1 |
| Lindenmayer, DB | 1 |
| Cunningham, RB | 1 |
| Donnelly, CF | 1 |
| Kusel, J | 1 |
| Hagan, P | 1 |
| Richter, J | 1 |
| Leman, JA | 1 |
| Small, G | 1 |
| Wilks, D | 1 |
| Tidman, MJ | 1 |
| Pütter, J | 1 |
| Held, F | 1 |
| el Tahir, KE | 1 |
| al-Kharji, AM | 1 |
| Ageel, AM | 1 |
| Bychkov, VG | 1 |
| Molokova, OA | 1 |
| Zuevskiĭ, VP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Observational Study to Assess the Performance of CAA Measurement as a Diagnostic Tool for the Detection of Schistosoma Haematobium Infections in Pregnant Women and Their Newborn and Child in Lambaréné, Gabon[NCT03779347] | Phase 3 | 100 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | ||
| S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT)[NCT00486863] | Phase 2 | 370 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Hemoglobin concentration in a venous blood sample collected at 14 and 32 weeks gestation was measured using a multi-analyte analyzer. Each participant's change in hemoglobin concentration between the two timepoints was determined, and the mean and standard deviation for each group calculated. (NCT00486863)
Timeframe: 14 weeks and 32 weeks gestation
| Intervention | grams/deciliter (Mean) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | -0.42 |
| Praziquantel at 12-16 Weeks Gestation | -0.44 |
Maternal fat stores were measured by thigh skinfold thickness obtained using a Holtain skinfold caliper. The thickness increase from 14 to 32 weeks was determined for each participant, and the mean and standard deviation calculated. (NCT00486863)
Timeframe: 14 and 32 weeks gestation
| Intervention | millimeters (Mean) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 0.08 |
| Praziquantel at 12-16 Weeks Gestation | 0.08 |
Maternal weight gain was assessed by measuring participants' weight in kilograms. The weight increase from 14 to 32 weeks was determined for each participant, and the mean and standard deviation calculated. (NCT00486863)
Timeframe: 14 and 32 weeks gestation
| Intervention | kilograms (Mean) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 0.33 |
| Praziquantel at 12-16 Weeks Gestation | 0.32 |
Birth weight was collected for live infants at the time of delivery by a trained midwife, or within 24 hours of delivery for participants who chose to deliver at home with a helot, a birth attendant without formal training. (NCT00486863)
Timeframe: Within 24 hours of delivery.
| Intervention | kilograms (Mean) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 2.85 |
| Praziquantel at 12-16 Weeks Gestation | 2.85 |
To assess total body iron, one needs to assess the storage compartment, which will contain sequestered iron, and the functional compartment, which represents bioavailable iron. Body iron status is defined by the two laboratory measurements that reflect these compartments, ferritin and serum transferrin receptor. The serum transferrin receptor:ferritin ratio has been shown in quantitative phlebotomy studies to provide an accurate assessment of total body iron over the entire range of status. At 14 and 32 weeks gestation, a blood sample was collected for assessment of total body iron by determination of the transferrin receptor:ferritin ratio. Each participant's change in ratio was calculated, and the median and interquartile range were determined for each group. (NCT00486863)
Timeframe: 14 weeks and 32 weeks gestation
| Intervention | ratio (Median) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 0.0 |
| Praziquantel at 12-16 Weeks Gestation | 0.0 |
Anemia of inflammation was assessed via maternal urine hepcidin levels. In response to inflammation, elevated serum levels of hepcidin is synthesized. Hepcidin causes sequestration of iron from bio-available forms to storage forms such as ferritin and decreases intestinal absorption of iron. Hepcidin was measured in participants' urine at 32 weeks gestation. (NCT00486863)
Timeframe: 32 weeks gestation
| Intervention | nanograms/milliliter (Median) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 2.58 |
| Praziquantel at 12-16 Weeks Gestation | 3.38 |
Abortion was defined by the protocol as bleeding followed by fetal loss as supported by ultrasound before 20 weeks gestation. Abortion was an important safety outcome measure due to the fact that abortion would occur closer to the time of dosing than miscarriage or stillbirth. Participants were observed in hospital for 24 hours after dosing and asked to return for any bleeding at any time. (NCT00486863)
Timeframe: After dosing and before 20 weeks gestation
| Intervention | participants (Number) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 0 |
| Praziquantel at 12-16 Weeks Gestation | 0 |
Participants were observed in hospital for 24 hours after dosing for serious adverse events. Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required in-patient hospitalization or prolongation thereof (for reasons other than the 24-hour observation period); resulted in a congenital anomaly/birth defect; or may have jeopardized the participant, or required intervention to prevent one of these outcomes. (NCT00486863)
Timeframe: Within 24 hours of dosing
| Intervention | participants (Number) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 0 |
| Praziquantel at 12-16 Weeks Gestation | 0 |
The newborn was examined by the midwife at delivery and within 2-6 days of delivery to assess the presence of congenital anomalies and well-being. The newborn was also examined by study pediatrician at 28 days of life. (NCT00486863)
Timeframe: At delivery, within 2-6 days of delivery, and at 28 days
| Intervention | participants (Number) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 1 |
| Praziquantel at 12-16 Weeks Gestation | 1 |
Each participant was followed until delivery to record if the outcome of the pregnancy was a live birth. Live births were defined as the complete expulsion or extraction from its mother of a product of conception, irrespective of the duration of the pregnancy, which, after such separation, breathes or shows any other evidence of life such as heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles, whether the umbilical cord had been cut or the placenta was attached. (NCT00486863)
Timeframe: At delivery
| Intervention | participants (Number) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 181 |
| Praziquantel at 12-16 Weeks Gestation | 181 |
Participants were assessed for the presence of pre-eclampsia at both the 22 and 32 week visits. Pre-eclampsia was defined by the presence of proteinurea (2+ protein on urine dipstick) and a single diastolic blood pressure reading of 100 millimiters of mercury (mm Hg) or above OR more than one reading, four hours apart, of 90 mm Hg or above. (NCT00486863)
Timeframe: 22 weeks and 32 weeks
| Intervention | participants (Number) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 0 |
| Praziquantel at 12-16 Weeks Gestation | 0 |
Parasitologic response to treatment was evaluated by counting S. japonicum eggs per gram of stool at screening and again at 22 weeks gestation. Success of treatment was pre-specified as greater than 90 percent reduction in egg count from screening to 22 weeks gestation. (NCT00486863)
Timeframe: Screening and 22 weeks gestation
| Intervention | participants (Number) |
|---|---|
| Placebo Control at 12-16 Weeks Gestation | 92 |
| Praziquantel at 12-16 Weeks Gestation | 157 |
Since pregnancy is associated with increased cytochrome P450 activity and physiologic changes in the gastrointestinal tract that tend to reduce drug absorption, praziquantel pharmacokinetics may be affected by pregnancy. Thus, the metabolite-to-parent drug ratio may serve as a differential marker to help determine if variability in drug exposure following oral administration during pregnancy is due to altered metabolism or drug absorption. Samples that were collected from subjects who were randomized to receive praziquantel were analyzed for praziquantel and 4-hydroxy praziquantel concentrations. Assays were performed using high performance liquid chromatography-electrospray mass spectrometry in the University of California at San Diego Pediatric Clinical Pharmacology Laboratory. Descriptive statistics were obtained for concentrations at each of the four sparse sampling timepoints. (NCT00486863)
Timeframe: 4.5 and 8 hours after the first praziquantel dose (subjects assigned to an even study number) or 6 and 10 hours after the first praziquantel dose (subjects assigned to an odd study number).
| Intervention | ng/ml (Median) | |||
|---|---|---|---|---|
| 4.5 Hours, n=50 | 6 Hours, n=49 | 8 Hours, n=50 | 10 Hours, n=49 | |
| Praziquantel at 12-16 Weeks Gestation | 4020.1 | 4590.8 | 5373.7 | 4304.1 |
To assess total body iron, the serum transferrin receptor:ferritin ratio was assessed in the infant. At delivery, a heel stick blood sample and a cord blood sample were collected for assessment of total body iron by determination of the transferrin receptor:ferritin ratio. (NCT00486863)
Timeframe: 0-6 days after delivery.
| Intervention | ratio (Median) | |
|---|---|---|
| Cord Blood | Heel Stick | |
| Placebo Control at 12-16 Weeks Gestation | 1.76 | 0.00 |
| Praziquantel at 12-16 Weeks Gestation | 1.33 | 0.00 |
Toxicity to maternal kidney and liver was assessed by laboratory parameters collected just before and 24 hours after dosing. Specifically, blood was drawn just before the dose at 12-16 weeks gestation to determine baseline blood urea nitrogen (BUN), creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin. Blood was then drawn 24 hours after the second part of the split dose and before discharge from the hospital to assess any changes in these parameters. Any values that were 1.1 times the upper limit of normal or greater for the parameter were considered abnormal. (NCT00486863)
Timeframe: Just before and 24 hours after dosing
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Blood Urea Nitrogen (BUN) Abnormal | Creatinine Abnormal | Aspartate Aminotransferase (AST) Abnormal | Alanine Aminotransferase (ALT) Abnormal | Bilirubin Abnormal | |
| Placebo Control at 12-16 Weeks Gestation | 127 | 23 | 8 | 13 | 127 |
| Praziquantel at 12-16 Weeks Gestation | 137 | 39 | 9 | 10 | 137 |
Toxicity to maternal bone marrow, kidney, and liver was assessed by laboratory parameters collected just before and 24 hours after dosing. Specifically, blood was drawn just before the dose at 12-16 weeks gestation to determine baseline complete blood count, including white blood count (WBC), platelets, and hemoglobin. Blood was then drawn 24 hours after the second part of the split dose and before discharge from the hospital to assess any changes in these parameters. White blood count was abnormal at or above 10,800 or at or below 3500 cells/square millimeter (sq mm), platelets were abnormal at or below 140,000 cells/sq mm, and hemoglobin was abnormal at or below 10.9 grams/deciliter (g/dL). (NCT00486863)
Timeframe: Just before and 24 hours after dosing
| Intervention | participants (Number) | ||
|---|---|---|---|
| White Blood Cell Abnormal | Platelets Abnormal | Hemoglobin Abnormal | |
| Placebo Control at 12-16 Weeks Gestation | 69 | 3 | 54 |
| Praziquantel at 12-16 Weeks Gestation | 60 | 0 | 56 |
Two plasma samples were collected during the overnight hospitalization from approximately 200 subjects that remained at the time of study modification to incorporate PK studies. Subjects had samples collected based on one of two sample collection strategies: 4.5 and 8 hr after the first praziquantel dose or 6 and 10 hr after the first praziquantel dose. Subjects randomized to an even study number were assigned to the 4.5 and 8 hour schedule. Subjects randomized to an odd study number were assigned to the 6 and 10 hour schedule. Samples only from subjects randomized to receive praziquantel were analyzed for praziquantel. Samples drawn from subjects randomized to the control group were not analyzed. Praziquantel concentrations (ng/ml) were assayed using high performance liquid chromatography-electrospray mass spectrometry in the University of California at San Diego Pediatric Clinical Pharmacology Laboratory. (NCT00486863)
Timeframe: 4.5 and 8 hours after the first praziquantel dose (subjects assigned to an even study number) or 6 and 10 hours after the first praziquantel dose (subjects assigned to an odd study number).
| Intervention | ng/mL (Median) | |||
|---|---|---|---|---|
| 4.5 Hours, n=50 | 6 Hours, n=49 | 8 Hours, n=50 | 10 Hours, n=49 | |
| Praziquantel at 12-16 Weeks Gestation | 814.7 | 945.2 | 687.8 | 422.2 |
10 reviews available for praziquantel and Pregnancy
| Article | Year |
|---|---|
Topics: Adult; Aging; Aluminum; Alzheimer Disease; Animals; Anti-Bacterial Agents; Artemisia annua; Body Mas | 2022 |
Paediatric and maternal schistosomiasis: shifting the paradigms.
Topics: Anthelmintics; Child; Communicable Diseases, Imported; Female; Humans; Praziquantel; Pregnancy; Preg | 2017 |
Acting beyond 2020: better characterization of praziquantel and promising antischistosomal leads.
Topics: Drug Discovery; Female; Humans; Praziquantel; Pregnancy; Schistosomiasis; Schistosomicides | 2018 |
Impact of hookworm infection and deworming on anaemia in non-pregnant populations: a systematic review.
Topics: Adolescent; Adult; Aged; Albendazole; Anemia; Anthelmintics; Child; Child, Preschool; Female; Hemogl | 2010 |
Administration of praziquantel to pregnant and lactating women.
Topics: Anthelmintics; Female; Humans; Lactation; Praziquantel; Pregnancy; Schistosomiasis | 2003 |
Schistosomiasis and pregnancy.
Topics: Animals; Female; Genitalia, Female; Humans; Mice; Morbidity; Placenta; Praziquantel; Pregnancy; Preg | 2007 |
[Hepatosplenic schistosomiasis: case report and clinical review].
Topics: Adult; Animals; Feces; Female; Hepatitis C; Humans; Infant, Newborn; Liver Diseases, Parasitic; Live | 1993 |
Genotoxic activity of praziquantel.
Topics: Animals; Antiplatyhelmintic Agents; Carcinogenicity Tests; Carcinogens; Clinical Trials as Topic; Cr | 1997 |
[Schistosoma intercalatum bilharziasis: clinical and epidemiological considerations].
Topics: Abortion, Spontaneous; Africa South of the Sahara; Animals; Antiplatyhelmintic Agents; Female; Gastr | 1997 |
Evolution of schistosomiasis-induced pathology after therapy and interruption of exposure to schistosomes: a review of ultrasonographic studies.
Topics: Adolescent; Adult; Aged; Animals; Anthelmintics; Child; Female; Follow-Up Studies; Gallbladder; Huma | 2000 |
21 trials available for praziquantel and Pregnancy
| Article | Year |
|---|---|
A cluster randomized controlled trial for assessing POC-CCA test based praziquantel treatment for schistosomiasis control in pregnant women and their young children: study protocol of the freeBILy clinical trial in Madagascar.
Topics: Anthelmintics; Antigens, Helminth; Child, Preschool; Clinical Trials, Phase III as Topic; Female; Hu | 2021 |
Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women Infected with Schistosoma japonicum.
Topics: Animals; Anthelmintics; Female; Humans; Lactation; Philippines; Praziquantel; Pregnancy; Schistosoma | 2020 |
Prospective, observational study to assess the performance of CAA measurement as a diagnostic tool for the detection of Schistosoma haematobium infections in pregnant women and their child in Lambaréné, Gabon: study protocol of the freeBILy clinical trial
Topics: Animals; Anthelmintics; Antigens, Helminth; Child, Preschool; Cross-Sectional Studies; Data Accuracy | 2020 |
Safety evaluation of a novel topical combination of esafoxolaner, eprinomectin and praziquantel, in reproducing female cats.
Topics: Animals; Cats; Female; Ivermectin; Male; Methoprene; Praziquantel; Pregnancy; Reproduction | 2021 |
Effect of maternal praziquantel treatment for Schistosoma japonicum infection on the offspring susceptibility and immunologic response to infection at age six, a cohort study.
Topics: Animals; Antiprotozoal Agents; Child; Cohort Studies; Cytokines; Double-Blind Method; Female; Humans | 2021 |
Effects of treating helminths during pregnancy and early childhood on risk of allergy-related outcomes: Follow-up of a randomized controlled trial.
Topics: Albendazole; Anthelmintics; Asthma; Child; Child, Preschool; Double-Blind Method; Female; Follow-Up | 2017 |
Maternal anemia type during pregnancy is associated with anemia risk among offspring during infancy.
Topics: Anemia; Anthelmintics; Antigens, CD; C-Reactive Protein; Female; Ferritins; Hemoglobins; Hepcidins; | 2019 |
Maternal, placental and cord blood cytokines and the risk of adverse birth outcomes among pregnant women infected with Schistosoma japonicum in the Philippines.
Topics: Adult; Anthelmintics; Cytokines; Female; Fetal Blood; Humans; Infant, Low Birth Weight; Infant, Newb | 2019 |
Effect of maternal Schistosoma mansoni infection and praziquantel treatment during pregnancy on Schistosoma mansoni infection and immune responsiveness among offspring at age five years.
Topics: Animals; Anthelmintics; Antibodies, Helminth; Child, Preschool; Female; Humans; Infant; Infant, Newb | 2013 |
Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Anthelmintics; Birth Weight; Double-Blind Method; Female; Fetus; Gestational Age; Humans; Inf | 2016 |
The impact of prenatal exposure to parasitic infections and to anthelminthic treatment on antibody responses to routine immunisations given in infancy: Secondary analysis of a randomised controlled trial.
Topics: Adult; Albendazole; Animals; Anthelmintics; Antibodies, Helminth; Antibody Formation; Female; Helmin | 2017 |
Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Antigens, Helminth; Cytokines; Female; Gene Expression Profiling; Humans; Praziqu | 2008 |
Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo-controlled trial.
Topics: Animals; Anthelmintics; Antibodies, Helminth; Antigens, Helminth; Double-Blind Method; Female; Human | 2009 |
Effects of deworming during pregnancy on maternal and perinatal outcomes in Entebbe, Uganda: a randomized controlled trial.
Topics: Albendazole; Anemia; Animals; Anthelmintics; Birth Weight; Double-Blind Method; Female; Helminthiasi | 2010 |
Effect of single-dose anthelmintic treatment during pregnancy on an infant's response to immunisation and on susceptibility to infectious diseases in infancy: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Albendazole; Anthelmintics; Communicable Diseases; Dose-Response Relationship, Drug; Double-B | 2011 |
Anthelminthic treatment during pregnancy is associated with increased risk of infantile eczema: randomised-controlled trial results.
Topics: Adult; Albendazole; Anthelmintics; Dermatitis, Atopic; Double-Blind Method; Female; Helminthiasis; H | 2011 |
Treatment with anthelminthics during pregnancy: what gains and what risks for the mother and child?
Topics: Albendazole; Ancylostomatoidea; Anemia; Animals; Anthelmintics; Benzimidazoles; Birth Weight; Child; | 2011 |
Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on immune responses to schistosome antigens among the offspring: results of a randomised, placebo-controlled trial.
Topics: Animals; Antibodies, Protozoan; Antigens, Protozoan; Antiprotozoal Agents; Cytokines; Female; Humans | 2011 |
The effect of anthelmintic treatment during pregnancy on HIV plasma viral load: results from a randomized, double-blind, placebo-controlled trial in Uganda.
Topics: Adult; Albendazole; Anthelmintics; Cohort Studies; Double-Blind Method; Female; Helminthiasis; HIV I | 2012 |
Evaluation of the safety of ivermectin-praziquantel administered orally to pregnant mares.
Topics: Administration, Oral; Animals; Anthelmintics; Drug Combinations; Female; Horses; Ivermectin; Praziqu | 2003 |
The impact of helminths on the response to immunization and on the incidence of infection and disease in childhood in Uganda: design of a randomized, double-blind, placebo-controlled, factorial trial of deworming interventions delivered in pregnancy and e
Topics: Albendazole; Animals; Antiparasitic Agents; Child; Double-Blind Method; Female; Helminthiasis; Helmi | 2007 |
34 other studies available for praziquantel and Pregnancy
| Article | Year |
|---|---|
Praziquantel Reduces Maternal Mortality and Offspring Morbidity by Enhancing Anti-Helminthic Immune Responses.
Topics: Animals; Anthelmintics; Antibody Formation; Cytokines; Female; Humans; Maternal Mortality; Mebendazo | 2022 |
Neurocysticercosis Complicating Pregnancy.
Topics: Albendazole; Anthelmintics; Female; Headache; Humans; Hydrocephalus; Infant, Newborn; Neurocysticerc | 2022 |
Investigation on birth weight outcomes in schistosomiasis and praziquantel research: a correspondence.
Topics: Birth Weight; Female; Fetus; Humans; Infant, Newborn; Praziquantel; Pregnancy; Schistosomiasis | 2023 |
Gendered lives, gendered Vulnerabilities: An intersectional gender analysis of exposure to and treatment of schistosomiasis in Pakwach district, Uganda.
Topics: Child; Delivery of Health Care; Female; Humans; Intersectional Framework; Male; Praziquantel; Pregna | 2023 |
Fast and reliable easy-to-use diagnostics for eliminating bilharzia in young children and mothers: An introduction to the freeBILy project.
Topics: Adult; Animals; Anthelmintics; Antigens, Helminth; Child; Child, Preschool; Female; Humans; Immunolo | 2020 |
A 38-year-old woman with zosteriform skin lesions.
Topics: Adult; Animals; Anthelmintics; Diagnosis, Differential; Female; Humans; Nucleic Acid Amplification T | 2017 |
Efficacy and safety of oral praziquantel against Dicrocoelium dendriticum in llamas.
Topics: Administration, Oral; Animals; Anthelmintics; Camelids, New World; Dicrocoeliasis; Dicrocoelium; Dos | 2013 |
Oral expulsion of taenia worm by a pregnant lady.
Topics: Abdominal Pain; Adult; Animals; Anthelmintics; Female; Humans; Praziquantel; Pregnancy; Pregnancy Co | 2012 |
Tubal ectopic gestation associated with genital schistosomiasis: a case report.
Topics: Adult; Anthelmintics; Female; Humans; Praziquantel; Pregnancy; Pregnancy, Tubal; Salpingectomy; Schi | 2014 |
Prevention of Lactogenic Toxocara cati Infections in Kittens by Application of an Emodepside/Praziquantel Spot-on (Profender®) to the Pregnant Queen.
Topics: Administration, Topical; Animals; Anthelmintics; Cat Diseases; Cats; Depsipeptides; Drug Combination | 2015 |
Tackling neglect: treating schistosomiasis in pregnancy.
Topics: Anthelmintics; Birth Weight; Female; Fetus; Humans; Praziquantel; Pregnancy; Schistosomiasis | 2016 |
Praziquantel for schistosomiasis in pregnancy.
Topics: Anthelmintics; Female; Humans; Praziquantel; Pregnancy; Schistosomiasis | 2016 |
A case report of Schistosoma haematobium infection in a pregnant migrant raises concerns about lack of screening policies.
Topics: Adult; Animals; Anthelmintics; Female; Humans; Male; Praziquantel; Pregnancy; Pregnancy Complication | 2016 |
Treatment and prevention of vertical transmission of Toxocara cati in cats with an emodepside/praziquantel spot-on formulation.
Topics: Animals; Anthelmintics; Cat Diseases; Cats; Depsipeptides; Drug Combinations; Feces; Female; Infecti | 2009 |
High tissue egg burden mechanically impairing the tubal motility in genital schistosomiasis of the female.
Topics: Adult; Animals; Diagnosis, Differential; Fallopian Tubes; Female; Genital Diseases, Female; Humans; | 2003 |
Schistosomiasis.
Topics: Animals; Anthelmintics; Female; Genome; Humans; Praziquantel; Pregnancy; Pregnancy Complications, Pa | 2004 |
[Extra uterine pregnancy associated with a tubal schistosomiasis due to Schistosoma haematobium. A case report from Niger].
Topics: Adult; Animals; Calcinosis; Combined Modality Therapy; Diagnosis, Differential; Eggs; Fallopian Tube | 2004 |
Prenatal Schistosoma japonicum infection in piglets: effect of repeated exposure of the dams on treatment efficacy and susceptibility to challenge infections.
Topics: Animals; Anthelmintics; Cecum; Disease Models, Animal; Disease Susceptibility; Feces; Female; Liver; | 2004 |
Is praziquantel therapy safe during pregnancy?
Topics: Abnormalities, Drug-Induced; Adult; Anthelmintics; Child, Preschool; Endemic Diseases; Female; Human | 2004 |
Praziquantel for the treatment of schistosomiasis mansoni during pregnancy.
Topics: Administration, Oral; Adult; Anthelmintics; Female; Humans; Praziquantel; Pregnancy; Pregnancy Compl | 2005 |
Endoscopic extraction of Fasciolopsis buski.
Topics: Adult; Animals; Duodenal Diseases; Duodenoscopy; Fasciolidae; Female; Humans; Praziquantel; Pregnanc | 2007 |
Ectopic cutaneous schistosomiasis-perigenital infiltrative granulomata in a 34-year-old French pregnant woman.
Topics: Administration, Oral; Adult; Anal Canal; Anthelmintics; Diagnosis, Differential; Female; France; Gra | 2008 |
Results of toxicological studies on praziquantel.
Topics: Animals; Carcinogens; Cricetinae; Dogs; Embryo, Mammalian; Female; Fertility; Half-Life; Humans; Int | 1984 |
[Genotoxicologic studies on pyquiton, a new antischistosomal agent (author's transl)].
Topics: Abnormalities, Drug-Induced; Animals; Female; Isoquinolines; Male; Mutagens; Praziquantel; Pregnancy | 1982 |
Mutagenic and teratogenic effects of anti-schistosomal praziquantel.
Topics: Abnormalities, Drug-Induced; Animals; Female; Isoquinolines; Mutagens; Praziquantel; Pregnancy; Rats | 1982 |
Asherman syndrome caused by schistosomiasis.
Topics: Adult; Amenorrhea; Cesarean Section; Fallopian Tubes; Female; Humans; Ovarian Diseases; Postoperativ | 1995 |
[A case from practice (272)--cerebral cysticercosis (neurocysticercosis)--infection with larvae of Taenia solium, swine tapeworm].
Topics: Adult; Animals; Brain Diseases; Cysticercosis; Female; Humans; Praziquantel; Pregnancy; Pregnancy Co | 1993 |
Case report: neurocysticercosis in pregnancy.
Topics: Adolescent; Anticonvulsants; Antiplatyhelmintic Agents; Brain Diseases; Cysticercosis; Epilepsy, Ton | 1996 |
The effects of parasites on a wild population of the Mountain Brushtail Possum (Trichosurus caninus) in south-eastern Australia.
Topics: Animals; Animals, Wild; Anthelmintics; Australia; Birth Rate; Eosinophils; Feces; Female; Helminthia | 1998 |
Praziquantel--its use, cost and possible development of resistance.
Topics: Africa; Animals; Anthelmintics; Child; Drug Resistance; Female; Humans; Oxamniquine; Praziquantel; P | 1999 |
Localized papular cutaneous schistosomiasis: two cases in travellers.
Topics: Adult; Antiparasitic Agents; Enzyme-Linked Immunosorbent Assay; Female; Humans; Praziquantel; Pregna | 2001 |
Quantitative studies on the occurrence of praziquantel in milk and plasma of lactating women.
Topics: Female; Humans; Isoquinolines; Lactation; Milk, Human; Praziquantel; Pregnancy; Time Factors | 1979 |
Effect of praziquantel and oxamniquine on prostacyclin synthesis by the rat arterial and myometrial tissues.
Topics: Animals; Aorta, Thoracic; Arachidonic Acid; Blood Pressure; Dose-Response Relationship, Drug; Epopro | 1992 |
[Granulomatous inflammation of the liver in opisthorchiasis].
Topics: Animals; Cricetinae; Dimethylnitrosamine; Female; Granuloma; Hydrocortisone; Liver; Mesocricetus; Op | 1987 |